CN116406296A - 狼疮发作的治疗 - Google Patents

狼疮发作的治疗 Download PDF

Info

Publication number
CN116406296A
CN116406296A CN202180068143.4A CN202180068143A CN116406296A CN 116406296 A CN116406296 A CN 116406296A CN 202180068143 A CN202180068143 A CN 202180068143A CN 116406296 A CN116406296 A CN 116406296A
Authority
CN
China
Prior art keywords
patient
patients
sle
baseline
bilag
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180068143.4A
Other languages
English (en)
Chinese (zh)
Inventor
R·卡利亚尼
G·阿布鲁
R·图玛拉
R·弗里
E·莫兰德
A·阿斯卡纳斯
E·维塔尔
K·卡鲁尼安
C·林德霍尔姆
E·马豪
C·克莱乌迪斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of CN116406296A publication Critical patent/CN116406296A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/28—Syringe ampoules or carpules, i.e. ampoules or carpules provided with a needle

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Lubricants (AREA)
  • Glass Compositions (AREA)
  • Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
CN202180068143.4A 2020-10-08 2021-10-07 狼疮发作的治疗 Pending CN116406296A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063089355P 2020-10-08 2020-10-08
US63/089355 2020-10-08
US202163178748P 2021-04-23 2021-04-23
US63/178748 2021-04-23
PCT/EP2021/077702 WO2022074123A1 (en) 2020-10-08 2021-10-07 Treatment of flares in lupus

Publications (1)

Publication Number Publication Date
CN116406296A true CN116406296A (zh) 2023-07-07

Family

ID=78269610

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180068143.4A Pending CN116406296A (zh) 2020-10-08 2021-10-07 狼疮发作的治疗

Country Status (11)

Country Link
US (1) US20240026015A1 (https=)
EP (1) EP4225791A1 (https=)
JP (1) JP2023546361A (https=)
KR (1) KR20230082659A (https=)
CN (1) CN116406296A (https=)
AU (1) AU2021356122B2 (https=)
BR (1) BR112023006328A2 (https=)
CA (1) CA3197055A1 (https=)
IL (1) IL301759A (https=)
TW (1) TW202237647A (https=)
WO (1) WO2022074123A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20231255T1 (hr) 2021-04-23 2024-02-02 Astrazeneca Ab Režim doziranja anti-ifnar1 za potkožnu injekciju
BR112023021868A2 (pt) * 2021-04-23 2023-12-19 Astrazeneca Ab Tratamento de lúpus eritematoso cutâneo
EP4587005A1 (en) 2022-09-14 2025-07-23 Viatris Asia Pacific Pte. Ltd. Sip 1 receptor modulators for use in the treatment of type 1 ifn mediated diseases
EP4545090A1 (en) * 2023-10-27 2025-04-30 Universität Leipzig Interferon-a receptor immune modulator for use as a medicament

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101678100A (zh) * 2006-12-06 2010-03-24 米迪缪尼有限公司 治疗系统性红斑狼疮的方法
WO2021094378A1 (en) * 2019-11-11 2021-05-20 Astrazeneca Ab Type i interferon inhibition in systemic lupus erythematosus
WO2021239928A2 (en) * 2020-05-29 2021-12-02 Astrazeneca Ab Treatment of cardiometabolic disease

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE035082T2 (en) 2004-06-21 2018-05-02 Squibb & Sons Llc Interferon alpha receptor 1 antibodies and their use
HRP20160855T1 (hr) 2008-02-08 2016-09-23 Medimmune, Llc Anti-ifnar1 protutijela sa smanjenim afinitetom fc liganda
US20120251546A1 (en) 2009-09-03 2012-10-04 Medimmune Llc Type 1 inteferon diagnostic
CA2995222C (en) 2015-08-19 2021-07-13 Medimmune, Llc Stable anti-ifnar1 formulation
CN106243226B (zh) * 2016-08-05 2019-02-12 北京智仁美博生物科技有限公司 抗人ifnar1的抗体及其用途

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101678100A (zh) * 2006-12-06 2010-03-24 米迪缪尼有限公司 治疗系统性红斑狼疮的方法
WO2021094378A1 (en) * 2019-11-11 2021-05-20 Astrazeneca Ab Type i interferon inhibition in systemic lupus erythematosus
WO2021239928A2 (en) * 2020-05-29 2021-12-02 Astrazeneca Ab Treatment of cardiometabolic disease

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ERIC MORAND等: "Efficacy and Safety of Anifrolumab in Patients with Moderate to Severe Systemic Lupus Erythematosus: Results of the Second Phase 3 Randomized Controlled Trial", Retrieved from the Internet <URL:https://acrabstracts.org/abstract/efficacy-and-safety-of-anifrolumab-in-patients-with-moderate-to-severe-systemic-lupus-erythematosus-results-of-the-second-phase-3-randomized-controlled-trial/> *
RICHARD FURIE等: "A Phase 3 Randomized Controlled Trial of Anifrolumab in Patients with Moderate to Severe Systemic Lupus Erythematosus", Retrieved from the Internet <URL:https://acrabstracts.org/abstract/a-phase-3-randomized-controlled-trial-of-anifrolumab-in-patients-with-moderate-to-severe-systemic-lupus-erythematosus/> *
RICHARD FURIE等: "Anifrolumab, an Anti–Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus", RTHRITIS & RHEUMATOLOGY, vol. 69, no. 2, 7 November 2016 (2016-11-07), pages 376 - 386, XP055652780, DOI: 10.1002/art.39962 *
RICHARD FURIE等: "Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial", THE LANCET RHEUMATOLOGY, vol. 1, no. 4, 31 December 2019 (2019-12-31), pages 208 *

Also Published As

Publication number Publication date
BR112023006328A2 (pt) 2023-05-09
TW202237647A (zh) 2022-10-01
AU2021356122A1 (en) 2023-06-08
CA3197055A1 (en) 2022-04-14
KR20230082659A (ko) 2023-06-08
IL301759A (en) 2023-05-01
US20240026015A1 (en) 2024-01-25
AU2021356122B2 (en) 2026-02-05
WO2022074123A1 (en) 2022-04-14
EP4225791A1 (en) 2023-08-16
JP2023546361A (ja) 2023-11-02

Similar Documents

Publication Publication Date Title
JP7484027B2 (ja) 皮下注射のための抗ｉｆｎａｒ１投薬計画
CN116406296A (zh) 狼疮发作的治疗
KR20220099985A (ko) 전신성 홍반성 루푸스에서 i형 인터페론 억제
JP2024519196A (ja) 皮膚エリテマトーデスの処置
US20250002591A1 (en) Inhibitor of type 1 interferon receptor steroid sparing in systemic lupus erythermatosus patients
CN118076379A (zh) 狼疮的治疗
CN117337305A (zh) 系统性红斑狼疮患者中的1型干扰素受体抑制剂类固醇节制
HK40087032B (en) Anti-ifnar1 dosing regime for subcutaneous injection
HK40087032A (en) Anti-ifnar1 dosing regime for subcutaneous injection
CN117677638A (zh) 狼疮的治疗
CN117157099A (zh) 用于皮下注射的抗ifnar1给药方案
CN121127499A (zh) 狼疮的治疗
EA052183B1 (ru) Лечение кожной красной волчанки
EA047082B1 (ru) Схема введения дозы антитела к ifnar 1 для подкожной инъекции

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination